Navigation Links
Exelixis Announces Third Quarter 2007 Financial Results and Business Update
Date:11/5/2007

pment-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 of clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statement

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential efficacy of XL647, the future development of our other compounds, the sufficiency of our resources to develop XL647 and our other compounds and pipeline, additional research funding to be received from Bristol-Myers Squibb, our estimated future revenues and expenses, our estimated future balances of cash and cash equivalents, short-term and long-term marketable securities, investments held by Symphony Evolution, Inc. and restricted cash and investments, and other matters discussed above under "Financial Outlook". Words such as "expect," "should," "initiate," "suggest," "may," "will" and "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are only predictions and are based upon our current plans, assumptions, beliefs and expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forw
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 Award winning unified communications ... four new-hosted collaboration bundles that combine next generation ... conferencing experiences for low, flat rate fees. ... businesses have optimized solutions to meet their technology ... audio only minutes (1K, 5K, 10K increments) or ...
(Date:10/1/2014)... , October 1, 2014 ... to software invited to engage around the theme, ,Commercial ...     Elsevier , ... products and services, will host a gathering of some ... issues and trends impacting healthcare today and in the ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... - 2014 Summary Global Markets Direct,s, ... - 2014, provides an overview of the Pacific ... This report provides comprehensive information on the ... LLC,s, complete with comparative analysis at various stages, ...
(Date:9/30/2014)... September 30, 2014 Proove Biosciences ... is excited to announce a new genetic test built ... Proove Pain Perception Test will provide physicians with ... why pain tolerance levels are stratified between individuals. With ... whether a person has a genetic predisposition that will ...
Breaking Biology Technology:SoundConnect Launches New Audio, Web and Video Bundles 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... DIEGO, Aug. 4 Cadence Pharmaceuticals,Inc. (Nasdaq: ... and commercializing proprietary product candidates principally,for use in ... and CEO Theodore Schroeder will present the company,s ... -- Bank of America,s 2008 Specialty Pharmaceuticals Conference ...
... Revenue Increases 76% from Same Prior Year Period, ... SUPG ), a pharmaceutical company dedicated to ... solid tumors and,hematological malignancies, today announced financial results ... 30, 2008., Total revenues for the 2008 ...
... 4 Joseph F. Finn, Jr.,C.P.A. ("Finn") announced today ... to him on July 28, 2008 for the benefit ... a common law,procedure, wherein Finn will liquidate the assets, ... sealed bid auction on October 10, 2008., Persons ...
Cached Biology Technology:Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008 2SuperGen Reports 2008 Second Quarter Financial Results 2SuperGen Reports 2008 Second Quarter Financial Results 3SuperGen Reports 2008 Second Quarter Financial Results 4SuperGen Reports 2008 Second Quarter Financial Results 5SuperGen Reports 2008 Second Quarter Financial Results 6SuperGen Reports 2008 Second Quarter Financial Results 7SuperGen Reports 2008 Second Quarter Financial Results 8SuperGen Reports 2008 Second Quarter Financial Results 9SuperGen Reports 2008 Second Quarter Financial Results 10SuperGen Reports 2008 Second Quarter Financial Results 11SuperGen Reports 2008 Second Quarter Financial Results 12SuperGen Reports 2008 Second Quarter Financial Results 13
(Date:9/30/2014)... KONG , Sept. 30, 2014 Winners of ... Economist Events, Innovation Summit scheduled to take place at the JW ... the summit, the award winners will share their experiences and the ... who have made a proven innovation over the past decade, will ... the night before the summit. It will be the first ...
(Date:9/29/2014)... September 29, 2014 -- Plants have a ... help the pants extract nutrients and defend against ... from contaminating fruits and vegetables. Now, scientist have ... inside of seeds; thus ensuring that sprouting plants ... the University of Notre Dame, presented their findings ...
(Date:9/29/2014)... Food and Brand Lab pilot study, published in ... National School Lunch Program (NSLP) by 9% and overall ... Move to Schools (CMTS), an initiative of Michelle Obama,s ... to provide nutrition instruction to students and culinary advice ... event was held in an Upstate New York high ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Plants prepackage beneficial microbes in their seeds 2Chefs move to schools can increase school meal participation and vegetable intake among students 2
... At a recent Kavli Futures Symposium, 19 experts from ... the lab to understand and exploit the evolution of organisms ... or other biotechnology products. Now, three of the participants ... raised during the meeting: Michael Brenner, Professor of Applied Mathematics ...
... Tampa, Fla. (June 28, 2011) Mensenchymal stem cells ... tissues, have been shown to be therapeutically effective in ... assisting in skin wound healing, and suppressing chronic airway ... are being prepared for therapeutic applications, they are cultured ...
... device to reduce the risk of infection, clotting and narrowing ... because of kidney failure. The device, designed to be ... a technician easy access to the patient,s bloodstream and could ... of a dialysis procedure. The prototype has not yet ...
Cached Biology News:Beyond Darwin: Evolving new functions 2Serum-free cultures help transplanted MSCs improve efficacy 2Student team invents device to cut dialysis risk 2
... generation of microarrays to detect alternative splicing. ... rapidly elucidate alternatively spliced events in gene ... discovery. The service combines ExonHits proprietary splice ... analysis with Agilents robust microarray platform. The ...
... EZ-Tn5™ Plasmid-Based Deletion Machine is based on ... system developed by Goryshin and Reznikoff, and ... nested families of deletions and inversions by ... a transposon-containing plasmid vector. Although most researchers ...
... kit I provides reagents and a protein standard ... reducing agents and detergents. The RC DC protein ... reagents and standards sufficient for 500 standard assays: ... reagent II, 250 ml alkaline copper tartrate solution, ...
... PROTECT FROM LIGHT. Useful in cell activation experiments when ... by TLC. Soluble in DMSO or EtOH. ... mM stock in DMSO is recommended. Microliter amounts of ... with rapid mixing (e.g. 10 μl into 5 ml ...
Biology Products: